Dynamic Duos: Expert Guidance on Optimally Rejuvenating Perioral Lines and Tear Troughs With HA Fillers (CME/CE Webcast)
Activity Description and Purpose
The eyes and mouth area are 2 of the most dynamic and distinguishing features of the human face. Both convey emotions and profoundly influence what is and what is not perceived as youthful and attractive. As a result, procedures to rejuvenate the tear troughs and infraorbital hollows under the eyes and the perioral region are in high demand. Hyaluronic acid (HA) gel fillers are less-invasive, nonsurgical treatment options that are gaining both acceptance and popularity. In this educational activity, a dynamic duo of experts will review best practices and supporting clinical data on the use of HA fillers to safely and successfully reduce rhytids and restore fullness in these areas. The desired results of this activity are to aid aesthetic clinicians in selecting the most effective and safe HA filler that will provide the wanted results in individual patients.
This educational activity is intended for aesthetic dermatologists, physician assistants, nurses, and nurse practitioners.
After completing this activity, participants will be better able to:
- Review which properties of hyaluronic acid fillers are best suited to achieve optimal rejuvenation of the perioral area of the face
- Describe best practices in injection technique used to treat perioral lines
- Apply clinical evidence to treat perioral lines in a variety of patients
- Review which properties of hyaluronic acid fillers are best suited to achieve optimal rejuvenation of tear troughs
- Describe best practices in injection techniques to treat tear troughs
|Joely Kaufman, MD, FAAD
Skin Associates of South Florida
Associate Professor of Dermatology
University of Miami Miller School of Medicine
Coral Gables, Florida
Wendy W. Lee, MD, MS
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Joely Kaufman, MD, receives royalties from AbbVie Inc; is an advisory board member of AbbVie Inc; is on the speakers bureau for Galderma and Revance Therapeutics, Inc; and is a contracted researcher AbbVie Inc, Croma-Pharma GmbH, Galderma, Hugel, Inc, Merz, Inc, and Revance Therapeutics, Inc.
Wendy W. Lee, MD, MS, is a consultant for Allergan, Evolus, Inc, Galderma, Horizon Therapeutics plc, Revance Therapeutics, Inc, RoC Skincare, RVL Pharmaceuticals, Inc, and Tarsus Pharmaceuticals, Inc; and is a contracted researcher for NovaBay Pharmaceuticals, Inc.
This activity was peer reviewed. The peer reviewer has no relevant financial relationships.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Learners must take the pretest, view the webcast, and complete a posttest and evaluation form to receive a certificate of completion. Your chosen session must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
ACCME Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Interprofessional Joint Accreditation Statement
In support of improving patient care, Amedco is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163.
Amedco LLC designates this activity for a maximum of 1.25 ANCC contact hours.
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant as well as in-kind support in the form of injectables from Revance Therapeutics, Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at firstname.lastname@example.org.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Amedco, MedEdicus LLC, or Revance Therapeutics, Inc.
This CME/CE activity is copyrighted to MedEdicus LLC ©2023. All rights reserved. 293
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC
- 1.25 Participation